|
JP2004532626A
(ja)
*
|
2001-03-15 |
2004-10-28 |
エリューシス セラピューティクス,インコーポレーテッド |
二重特異性分子のポリクローナル集団、ならびにそれらの産生方法および使用
|
|
EP1483383A4
(en)
*
|
2002-02-15 |
2007-10-24 |
Cygene Inc |
METHODS AND COMPOSITIONS FOR THE CLEANING OF PATHOGENS IN VIVO
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US8093357B2
(en)
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
WO2003095626A2
(en)
*
|
2002-05-13 |
2003-11-20 |
Elusys Therapeutics, Inc. |
Purified composition of bispecific molecules and methods of production
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US20040180054A1
(en)
*
|
2003-03-13 |
2004-09-16 |
Hanmi Pharm. Co., Ltd. |
Physiologically active polypeptide conjugate having prolonged in vivo half-life
|
|
US20050176108A1
(en)
*
|
2003-03-13 |
2005-08-11 |
Young-Min Kim |
Physiologically active polypeptide conjugate having prolonged in vivo half-life
|
|
JP2007525446A
(ja)
*
|
2003-03-28 |
2007-09-06 |
エルシス セラピューティクス, インク. |
抗体活性の転換のための方法及び組成物
|
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20090036327A1
(en)
*
|
2003-07-08 |
2009-02-05 |
Trex Enterprises Corp. |
Method for chemical treatment of porous silicon surface
|
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
|
BRPI0406605B8
(pt)
|
2003-11-13 |
2021-05-25 |
Hanmi Holdings Co Ltd |
conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
|
|
US7276585B2
(en)
|
2004-03-24 |
2007-10-02 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
|
CA2585849A1
(en)
*
|
2004-10-29 |
2006-05-11 |
Elusys Therapeutics, Inc. |
Use of cr1-binding molecules in clearance and induction of immune responses
|
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
|
US9200079B2
(en)
|
2004-11-12 |
2015-12-01 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US20060134694A1
(en)
*
|
2004-12-22 |
2006-06-22 |
Intel Corporation |
Methods of protein profiling by thiolation
|
|
EP1893241A2
(en)
*
|
2005-04-28 |
2008-03-05 |
Ventana Medical Systems, Inc. |
Fluorescent nanoparticles conjugated to antibodies via a peg linker
|
|
US20060246523A1
(en)
|
2005-04-28 |
2006-11-02 |
Christopher Bieniarz |
Antibody conjugates
|
|
DK1931709T3
(en)
|
2005-10-03 |
2017-03-13 |
Xencor Inc |
FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
|
|
JP4860703B2
(ja)
|
2005-10-06 |
2012-01-25 |
ゼンコー・インコーポレイテッド |
最適化された抗cd30抗体
|
|
CN104090095B
(zh)
|
2005-11-23 |
2016-06-01 |
文塔纳医疗系统公司 |
分子缀合物
|
|
EP1968643A2
(en)
*
|
2005-12-16 |
2008-09-17 |
Diatos |
Cell penetrating peptide conjugates for delivering of nucleic acids into a cell
|
|
WO2007097934A2
(en)
*
|
2006-02-17 |
2007-08-30 |
Elusys Therapeutics, Inc. |
Methods and compositions for using erythrocytes as carriers for delivery of drugs
|
|
DE102006011507A1
(de)
|
2006-03-14 |
2007-09-20 |
Lts Lohmann Therapie-Systeme Ag |
Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
|
|
RS53263B
(sr)
|
2006-08-14 |
2014-08-29 |
Xencor Inc. |
Optimizovana antitela usmerena na cd19
|
|
EP2064240A2
(en)
|
2006-09-18 |
2009-06-03 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
|
US7935345B2
(en)
|
2007-05-21 |
2011-05-03 |
Children's Hospital & Research Center At Oakland |
Monoclonal antibodies that specifically bind to and neutralize bacillus anthracis toxin, compositions, and methods of use
|
|
WO2009048494A1
(en)
*
|
2007-07-30 |
2009-04-16 |
Trex Enterprises Corporation |
Method of chemical treatment of porous silicon surfaces
|
|
KR101616758B1
(ko)
|
2007-12-26 |
2016-04-29 |
젠코어 인코포레이티드 |
FcRn에 대한 변경된 결합성을 갖는 Fc 변이체
|
|
US12492253B1
(en)
|
2008-02-25 |
2025-12-09 |
Xencor, Inc. |
Anti-human C5 antibodies
|
|
US20100136584A1
(en)
*
|
2008-09-22 |
2010-06-03 |
Icb International, Inc. |
Methods for using antibodies and analogs thereof
|
|
WO2010033913A1
(en)
*
|
2008-09-22 |
2010-03-25 |
Icb International, Inc. |
Antibodies, analogs and uses thereof
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
|
BR112013031028A2
(pt)
|
2011-06-03 |
2016-11-29 |
3M Innovative Properties Co |
conectores heterobifuncionais com segmentos de polietileno glicol e conjugados de modificadores de resposta imunológica feitos a partir deles
|
|
EP3153180A1
(en)
*
|
2011-06-03 |
2017-04-12 |
3M Innovative Properties Company |
Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
|
|
US9239332B2
(en)
|
2011-07-11 |
2016-01-19 |
Indi Molecular, Inc. |
Akt-specific capture agents, compositions, and methods of using and making
|
|
JP6158090B2
(ja)
*
|
2011-10-31 |
2017-07-05 |
ダニエル・ジェイ・カポン |
非ペプチドヒンジ部含有フレキシブル抗体様分子
|
|
MX349035B
(es)
|
2012-05-17 |
2017-07-07 |
Extend Biosciences Inc |
Portadores para el suministro mejorado de farmaco.
|
|
CA2883707A1
(en)
*
|
2012-08-28 |
2014-03-06 |
The Governors Of The University Of Alberta |
Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods of making and using thereof
|
|
WO2016065052A1
(en)
|
2014-10-22 |
2016-04-28 |
Extend Biosciences, Inc. |
Insulin vitamin d conjugates
|
|
US9789197B2
(en)
|
2014-10-22 |
2017-10-17 |
Extend Biosciences, Inc. |
RNAi vitamin D conjugates
|
|
US9585934B2
(en)
|
2014-10-22 |
2017-03-07 |
Extend Biosciences, Inc. |
Therapeutic vitamin D conjugates
|
|
US9913875B2
(en)
|
2015-03-16 |
2018-03-13 |
California Institute Of Technology |
Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
|
|
IL256833B2
(en)
*
|
2015-07-15 |
2025-07-01 |
California Inst Of Techn |
IL-17F-specific binding agents, compositions and methods of use and preparation
|
|
WO2017176769A1
(en)
|
2016-04-04 |
2017-10-12 |
Indi Molecular, Inc. |
Cd8-specific capture agents, compositions, and methods of using and making
|
|
EP3519425B1
(en)
|
2016-09-29 |
2024-02-28 |
Indi Molecular, Inc. |
Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same
|
|
EP3638687A1
(en)
|
2017-06-15 |
2020-04-22 |
Indi Molecular, Inc. |
Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
|
|
US12201679B2
(en)
|
2019-04-05 |
2025-01-21 |
Institute For Systems Biology |
Epitope-targeted peptide immunostimulants
|
|
US12216122B2
(en)
|
2019-05-20 |
2025-02-04 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1)
|
|
US12209142B2
(en)
|
2020-05-29 |
2025-01-28 |
Institute For Systems Biology |
SARS-CoV-2 epitope-targeted peptide immunostimulants
|
|
CN111557902A
(zh)
*
|
2020-07-03 |
2020-08-21 |
中国人民解放军总医院 |
一种负载阿仑膦酸钠的可注射聚乙二醇水凝胶的制备方法与应用
|
|
WO2022098743A1
(en)
|
2020-11-03 |
2022-05-12 |
Indi Molecular, Inc. |
Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
|
|
US12233115B2
(en)
|
2022-09-30 |
2025-02-25 |
Extend Biosciences, Inc. |
Long-acting parathyroid hormone
|